At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Enzastaurindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Enzastaurin in Participants With Follicular Lymphoma
In Brief
A Phase 2 clinical trial evaluating Enzastaurin for Lymphoma, Follicular. Completed, enrolled 66 participants across 23 sites in 2 countries.
Detailed Summary
To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in participants with Follicular Lymphoma (FL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Follicular
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2007
Primary CompletionApr 2012
Study CompletionDec 2014
TodayJul 2026
First PostedMay 21, 2007
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.1 years ago
Interventions
Enzastaurindrug
Administered orally